Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.
First Wave BioPharma, Inc. (NASDAQ: FWBI), now operating as Entero Therapeutics, Inc., generates news primarily as a clinical-stage biopharmaceutical company focused on targeted, non-systemic therapies for gastrointestinal (GI) diseases. Company press releases describe a pipeline that has included biologic and small-molecule candidates such as adrulipase, latiglutenase, capeserod, and niclosamide for a range of GI indications.
News coverage for FWBI has highlighted multiple themes. One recurring category involves capital markets and financing transactions, including registered direct offerings and private placements of common stock and warrants, with stated uses of proceeds for working capital and general corporate purposes. These updates often reference shelf registration statements on Form S-3 and the role of placement agents.
Another important news stream relates to clinical and scientific developments. Releases have discussed Phase 2 clinical trial data for latiglutenase in celiac disease, invited papers in peer-reviewed journals, and abstracts accepted for presentation at major conferences such as Digestive Disease Week. These communications describe work on quantitative mucosal scales and serologic diagnostics in celiac disease, as well as the potential role of latiglutenase as an oral biotherapeutic.
Corporate and strategic news items have included the completion of a business combination with ImmunogenX, Inc., bringing latiglutenase into the GI-focused pipeline, and participation in investor and healthcare conferences where management presents the company’s development strategy and anticipated milestones.
Investors following FWBI-related news can use this page to review historical announcements about GI pipeline evolution, scientific publications, financing activities, and corporate transactions associated with the company that transitioned to Entero Therapeutics, Inc.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 25, 2023, First Wave BioPharma announced significant progress in its Phase 2 SPAN clinical trial for adrulipase, a treatment aimed at exocrine pancreatic insufficiency (EPI) in cystic fibrosis patients. The company has surpassed the 50% enrollment target with three U.S. trial sites actively screening patients. The study is a dose-escalation trial involving 12 patients, focusing on safety, tolerability, and efficacy, with topline results expected in July 2023. Adrulipase is a recombinant lipase enzyme designed to aid fat digestion and reduce malabsorption symptoms. Approximately 40,000 U.S. patients suffer from EPI due to cystic fibrosis.
First Wave BioPharma (NASDAQ: FWBI) announced a private placement agreement to issue 1,023,018 shares of common stock at $3.91 each, raising approximately $4.0 million before fees. The agreement includes warrants for an additional 2,046,036 shares at an exercise price of $3.66, valid for five years. The private placement is expected to close around March 15, 2023, subject to customary conditions. Proceeds will be used for working capital. The company plans to file a registration statement for resale of the shares with the SEC shortly. This offering adheres to SEC regulations, limiting sales to registered entities.